Top Stock Movers Oct 13, 2026: Why JBDI, TCRT, FLYE Surged

JBDI — JBDI Holdings Ltd (+245.0%)

JBDI closed up 245.0% at $3.45 on 445,470,932 shares. That is about 20 times its 20-day average of 22,291,814. Market cap was only $19.0M. One outside source put the day's gain nearer 446%, likely because it measured at a different time.

The catalyst is a $900 million acquisition. On October 12, JBDI signed a share purchase agreement to buy Glorian Capital Ltd., paid entirely in convertible promissory notes, according to its SEC Form 6-K. Glorian's subsidiary Flicknmix runs ZYMIX, a London-based AI social networking app. The deal would move the Singapore container-recycling company into consumer AI services. The notes convert at $1.00 per share, which creates large dilution risk. Closing is targeted for around October 30, 2026, per TipRanks.

On the chart, the candle was an inverted hammer. RSI was 86, which is very overbought. ADX was 41, the moving-average stack was bullish, and the stock sat at a 52-week high after a +100.0% gap (an opening price far above the prior close). StockSetups scored it 100/100 for conviction (grade A+), with relative strength of 99 and a trend-template score of 8.

The squeeze score was a modest 27/100. Free float (shares available to trade) was 23.5%, short interest was 38,691 shares, and days to cover was 6.8. Smart-money score was 50/100, with five 13D/G stakes and a largest disclosed stake of 46.0%. A move this large on a pending, dilutive deal is risky, and the deal may not close.

TCRT — Alaunos Therapeutics, Inc. (+187.1%)

TCRT closed up 187.1% at $3.02 on 197,844,702 shares, against a 20-day average of 12,592,799. Market cap was $2.6M.

Alaunos completed its acquisition of Velaris Therapeutics and closed a roughly $350 million private placement on October 13, per its 8-K. Velaris is a private biotech focused on pulmonary arterial hypertension and related cardiopulmonary diseases. Investorideas Newswire reported the oversubscribed placement was led by Fairmount and is expected to fund operations into 2029. Its intraday figures were smaller than the closing gain.

Context matters: on October 9 the company filed an 8-K flagging delisting risk. The stock had a +66.7% gap and still sat 30.9% below its 52-week high.

Technically, the candle was a three outside up (a bullish reversal pattern). RSI was 81 and ADX 54. The moving-average stack was mixed, conviction was 73/100 (grade B), and trend-template was 4. Squeeze score was 13/100, with free float of 77.7%, short interest of 5,707 shares and 0.3 days to cover. This looks like a news-driven move, not a squeeze. It also drew a small mention on r/pennystocks (rank #90).

FLYE — Fly-E Group, Inc. (+79.5%)

FLYE closed up 79.5% at $3.68 on 28,926,869 shares, about 3.5 times its 20-day average of 8,354,984. Market cap was $3.4M.

No news, filing or announcement explains the move. The only recent filing was an 8-K/A on management from September 14. The move looks momentum- or technically-driven. A kalkine.ca headline grouped it with other small-cap risers that day.

The gap was +5.6%, so most of the gain came during the session. RSI was 79 and ADX 32. The moving-average stack was mixed, and the stock remained 77.1% below its 52-week high. Conviction was 73/100 (grade B), relative strength was 88 and trend-template was 4.

The squeeze setup was weak. Score was 2/100, free float was 82.2%, short interest was 2,562 shares and days to cover was 0.4. A short squeeze is when short sellers are forced to buy back shares and push the price higher. These numbers don't point to one. FLYE was also among the movers on Oct 8, so it has been volatile.

PFAI — Pinnacle Food Group Ltd (+77.8%)

PFAI closed up 77.8% at $4.64 on 12,834,288 shares, about 5.7 times its 20-day average of 2,241,498. Market cap was $2.6M. Some sources cited a gain of about 93% intraday, which differs from the closing figure.

The likely catalyst is a development announcement, not a deal or financing. Subsidiary Pinnacle Food AgTech HK completed its first bench-scale fermentation of a yeast strain designed to produce recombinant human lactoferrin, per RTTNews. GuruFocus said it was developed with Bioboost Synbio Consulting and framed it as a safer, cheaper route. A TipRanks headline dated October 8 covered the same milestone, so the news may predate October 13.

The gap was +129.1%, so the stock opened far above the prior close, and it finished well off its highs for the day. It sat 8.5% below its 52-week high. RSI was 60, ADX 27 and the moving-average stack was bullish. Conviction was 96/100 (grade A+), relative strength was 97 and trend-template was 7.

Squeeze score was 26/100. Free float was 88.1%, short interest was 10,890 shares and days to cover was 7.6. PFAI also appeared in our Oct 7 recap. A big gap like this can fill; see gap fill strategy.

BKYI — BIO KEY INTERNATIONAL INC (+71.5%)

BKYI closed up 71.5% at $2.83 on 63,054,516 shares, about 5.3 times its 20-day average of 11,919,537. Market cap was $2.3M.

The most likely catalyst is BIO-key's October 13 announcement that a Middle East government security agency became a new customer. The agency chose its multi-factor authentication and single sign-on platform to protect critical communications infrastructure. Benzinga said the stock surged more than 130% in premarket trading, and financial terms were not disclosed. Other coverage credits a partnership with Dubai-based Al Majlis Group and a FIDO certification for Passkey:YOU. The company also named Stephen Morrow President of PortalGuard. Sources differ on which announcement drove the trading.

Caution: filings include an October 2 8-K tagged as dilution (bearish) and an October 9 S-1. The gap was +149.7%, so the stock gave back much of its opening gain. It remained 72.5% below its 52-week high.

Technically, RSI was 57 and ADX 32. The moving-average stack was mixed, relative strength was just 8, conviction was 38/100 (grade D) and trend-template was 2. Squeeze score was 13/100, with free float of 90.6%, short interest of 10,889 shares and 0.3 days to cover. The chart is weak apart from today's spike.

The bottom line

These are the day's most volatile names. Most are micro-caps with deal, financing or dilution risk. Big one-day gainers often give much of the move back, and patterns and squeezes fail. Don't treat a surge as a signal to chase. Size positions carefully, use defined risk, and do your own research. This is educational content, not financial advice.

StockSetups scans the full US universe after every close and every premarket morning. Compare today with the Oct 12 recap.